MP49-05 PRETREATMENT ABSOLUTE MONOCYTE COUNT IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB

Koichiro Ogihara,Eiji Kikuchi,Takashi Okabe,Ryo Yamashita,Shunsuke Yoshimine,Suguru Shirotake,Ryuto Nakazawa,Kazuhiro Matsumoto,Ryuichi Mizuno,Satoshi Hara,Masafumi Oyama,Takeshi Masuda,Masashi Niwakawa,Mototsugu Oya

MP49-05 PRETREATMENT ABSOLUTE MONOCYTE COUNT IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB

2020

Koichiro Ogihara
Eiji Kikuchi
Takashi Okabe
Ryo Yamashita
Shunsuke Yoshimine
Suguru Shirotake
Ryuto Nakazawa
Kazuhiro Matsumoto
Ryuichi Mizuno
Satoshi Hara
Masafumi Oyama
Takeshi Masuda
Masashi Niwakawa
Mototsugu Oya

INTRODUCTION AND OBJECTIVE:No reliable biomarker is available for predicting worse clinical outcome in chemo-resistant urothelial carcinoma (UC) patients treated with pembrolizumab. We focused on a...

Keywords:

urothelial carcinoma
Urology
Pembrolizumab
Biomarker (medicine)
Medicine
Monocyte count

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations